Slide 1: Daré Bioscience Corporate Presentation: September 12, 2022
1 DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” Daré Bioscience NASDAQ: DARE www.darebioscience.com Corporate Presentation: September 12, 2022 ©2022 Daré Bioscience | All rights reserved EXHIBIT 99.1
Slide 2: Forward-Looking Statements; Disclaimers
Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. (“Daré” or the “Company”). This presentation includes certain information obtained from trade and st
Slide 3: Women's Health is Our Sole Focus
3 Women’s Health is Our Sole Focus Daré Bioscience is a biopharmaceutical company committed to addressing the lack of innovation in women’s health with differentiated products that address unmet needs primarily in the areas of contraception, fertility, and vaginal and sexual health. Women’s Health i
Slide 4: Women's Health – Compelling Markets Where Innovation Matters
4 Women’s Health – Compelling Markets Where Innovation Matters ~73 Million women ages 15-491 1st hormonal monthly IVR, NuvaRing, ~$900M at peak2 1st hormonal IUD, Mirena franchise, ~$1.2B at peak3 1st copper IUD, still ~$200M/yr 40 years post launch4 Contraception Vaginal Health Sexual Health Fertil
Slide 5: Daré Portfolio – The Big Ideas
5 Daré Portfolio – The Big Ideas Contraception Vaginal Health Sexual Health Fertility Ovaprene ® - 1st Hormone-free, Monthly Contraception ADARE-204/214 - 1st 6 & 12-Month Injectable Contraception DARE-LARC1 - 1st Long-Acting, Reversible Personal Contraceptive System DARE-RH1 - Hormone-free contrace
Slide 6: Daré Bioscience: A Compelling Opportunity
1 Diverse pipeline with independent outcomes One FDA-approved product and several clinical development stage candidates utilizing different APIs and targeting different indications Multiple novel delivery platforms Persistent unmet needs require creative new approaches designed for her; Novel delive
Slide 7: Advancing Products Women Want – The Portfolio Snapshot
DARE-HRT1^ Hormone Therapy Phase 1 Study Topline Data Announced June 2021; Phase 1 / 2 Study Commenced 2Q 2022 DARE-FRT1/PTB1^ Pregnancy Maintenance Phase 1 Study Preparation DARE-VVA1^ Vulvar and Vaginal Atrophy Phase 1 /2 Study Commenced 2021 DARE-LARC1^ Long-Acting, Reversible Personal Contracept
Slide 8: Advancing Products Women Want – Late Stage Programs
8 • Investigational hormone-free, monthly intravaginal contraceptive. • Designed to be an easy-to-use monthly option with effectiveness approaching hormonal methods. There are currently no FDA-approved monthly hormone-free contraceptives. • Commercial license agreement with Bayer. Pivotal study coll
Slide 9: Advancing Products Women Want – Phase 1 and Preclinical
9 1. First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. 2. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days. 3. Potential to be the first convenient monthly format product with bo
Slide 10: Innovative women's health pipeline with multiple milestones anticipated in 2022
10 Innovative women’s health pipeline with multiple clinical, regulatory and commercial milestones anticipated in 2022. Every program, if approved, represents a potential first-line or first-in-class product opportunity. Experienced Board of Directors and Management Team with demonstrated success in
Slide 11: Experienced Management & Board of Directors
11 Experienced Management & Board of Directors Sabrina Martucci Johnson, MSc, MIM President & CEO John Fair Chief Strategy Officer Lisa Walters-Hoffert Chief Financial Officer David Friend, PhD Chief Scientific Officer Mark Walters Vice President of Operations Christine Mauck, MD, MPH Medical Direct
Slide 12: XACIATO (Clindamycin Phosphate) Vaginal Gel, 2%
12 DARE- BV1 Clindamycin 2% gel for Bacterial Vaginosis XACIATOTM (Clindamycin Phosphate) Vaginal Gel, 2% FDA approved for the treatment of bacterial vaginosis, the most common vaginal condition in women of reproductive age One-time intravaginal administration NDA approved December 7, 2021 QIDP, Fas
Slide 13: Bacterial Vaginosis
Bacterial Vaginosis 13 • Recurring infection, difficult to treat effectively • Most common vaginal condition in women ages 15-44 • Affects ~21 million women in the US1 • Bacterial Vaginosis increases health risks2, including increased risk of preterm birth, sexually transmitted infections, post-surg
Slide 14: XACIATO: Overview
14 XACIATO: Overview ➤XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. ➤ This marks the first FDA-approved product in Daré’s portfolio of potential first-in
Slide 15: XACIATO - Commercial License Agreement with Organon
15 XACIATO - Commercial License Agreement with Organon1 March 2022 – Organon and Daré announced they entered into an agreement whereby Organon will license global rights to XACIATO. The license became effective June 2022. Organon is a global healthcare company formed through a spin-off from Merck &
Slide 16: XACIATO Important Safety Information
16 XACIATO Important Safety Information* Indication Dosage & Administration Contraindications Warnings & Precautions Adverse Reactions XACIATO (clindamycin phosphate) vaginal gel is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and
Slide 17: XACIATO Use in Special Populations
17 XACIATO Use in Special Populations* Special Populations Special Populations Special Populations • Other clindamycin vaginal products have been used to treat pregnant women during the second and third trimester. XACIATO has not been studied in pregnant women. However, based on the low systemic abs
Slide 18: Ovaprene®
18 Ovaprene® Investigational potential first-in-category, hormone-free, monthly birth control U.S. Commercialization Collaborator: Phase 3 Development Collaborator:
Slide 19: Contraception: Large Market Opportunity
19 Contraception: Large Market Opportunity Women in the Reproductive Health & Contraception Market Segment (over 60 million women) Mirena® Hormone IUD (levonorgestrel-releasing intrauterine system) 52mg Physician inserted, long-acting. low/locally delivered hormone IUS 2020 worldwide sales: €1.2 bil
Slide 20: Ovaprene® - Potential Market Opportunity
20 Ovaprene® - Potential Market Opportunity There are approximately 65 million women in the US Aged 15-441 12 Million Current Non-Users 11 Million Current Hormone-free Product Users 12 Million Current Hormonal Product Users 35 Million Women2,3 Potential Candidates for Ovaprene® •Pill (10.3M) •Inject
Slide 21: Contraception: What's Missing from Current Hormone-Free Options?
21 Contraception: What’s Missing from Current Hormone-Free Options? Hormone-free Options Pregnancies Expected (per 100 women) 1,* Spermicides & Vaginal Gels 2 Condoms (male) Diaphragms (with a spermicide) Easy-to-use monthly option Copper IUD >27 18 12 Effectiveness approaching hormonal methods <1 L
Slide 22: Ovaprene® Investigational Hormone-Free, Monthly Contraceptive
22 Ovaprene® Investigational Hormone-Free, Monthly Contraceptive Spermiostatic Environment6 Contraceptive-loaded silicone ring releasing non-hormonal active Ferrous gluconate Physical Barrier 6 Three-dimensional, knitted polymer barrier 1.https://www.urban.org/urban-wire/women-want-effective-birth-c
Slide 23: Ovaprene® - Commercial License Agreement with Bayer
23 Ovaprene® - Commercial License Agreement with Bayer1 January 2020 - Bayer, which markets the $1 billion Mirena contraceptive franchise, and Daré announced the execution of a license agreement under which Bayer may commercialize Ovaprene investigational contraceptive in the US once approved by FDA
Slide 24: Ovaprene® - Collaborative Research Agreement with NIH
24 Ovaprene® - Collaborative Research Agreement with NIH1 July 2021 – Daré announced that funding and clinical operations support for the Phase 3 will be provided by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the
Slide 25: Ovaprene® - U.S. Regulatory Strategy
25 Ovaprene® - U.S. Regulatory Strategy1 Step 1 (Completed) •Postcoital Test (PCT) Clinical Study - Completed 4Q 2019 Step 2 (Ongoing) 1 - Obtain FDA approval of investigational device exemption (IDE) to support 2022 pivotal study start. 2 - Conduct pivotal study • ~200 subjects completing 12 months
Slide 26: Sildenafil Cream, 3.6%
26 Sildenafil Cream, 3.6% Potential First-In-Category treatment for Female Sexual Arousal Disorder (FSAD), which has no FDA-approved therapies Novel cream formulation of sildenafil to treat FSAD, utilizing active ingredient in Viagra®
Slide 27: FSAD – The Clinical Issue
The condition should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctions, such as orgasmic disorder (anorgasmia) and hypoactive sexual desire disorder (HSDD), which is characterized as lack or absence of sexual fantasies and desire for sexual activi
Slide 28: FSAD – What is the incidence?
28 FSAD – What is the incidence? Meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%.1 Market research estimates: ➤33% of US women aged 21 to 60 (~ 20 million women), experience
Slide 29: Sildenafil Cream, 3.6% - Product Profile
29 Sildenafil Cream, 3.6% - Product Profile ➤A PDE5 inhibitor utilized in ED medications for men – ED product Viagra® peaked at $2.05 billion in sales in 2012.2 ➤Designed to increase local blood flow to provide improvement in genital arousal response. ➤Applied topically, avoiding hepatic first-pass
Slide 30: Sildenafil Cream, 3.6% - Phase 2b Ongoing
30 Sildenafil Cream, 3.6% - Phase 2b Ongoing Phase 2b clinical study aims to evaluate Sildenafil Cream vs. placebo over 12 weeks of dosing following both a non-drug and placebo run-in period. ➤Compares Sildenafil Cream vs. placebo used in patients’ home setting. ➤Primary endpoint: patient reported o
Slide 31: Oral Sildenafil provided a compelling proof of concept for FSAD
31 Oral Sildenafil provided a compelling proof of concept for FSAD † Question #2 – “After taking study medication, the sensation/feeling in my genital (vaginal, labia, clitoris) area during intercourse or stimulation (foreplay) seemed to be: (a) more than before, (b) less than before, or (c) unchang
Slide 32: Sildenafil Cream, 3.6% - Phase 1 and Phase 2a Study Results
32 Phase 1 Study Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)1 Normal healthy postmenopausal women were dosed with escalating doses of Sildenafil Cream, 3.6%, using a cross-over study design. •Sildenafil Cream had significantly lower systemic exposure compared to a 50 mg oral sildenafil dose •
Slide 33: Sildenafil Cream, 3.6% - Thermography Study Results
33 Sildenafil Cream, 3.6% - Thermography Study Results* Demonstrated time to effect (See Figure 1) •Positive cognitive arousal responses were noted. •Significantly greater increases in genital temperature after application of Sildenafil Cream compared to placebo cream. •Significantly greater self-re
Slide 34: Phase 1 and Preclinical Programs
34 Phase 1 and Preclinical Programs New investigational prescription drug delivery options for women 34
Slide 35: Advancing Products Women Want – Phase 1 and Preclinical
35 1. First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. 2. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days. 3. Potential to be the first convenient monthly format product with b
Slide 36: Intravaginal Ring (IVR) Technology Highlights
36 Intravaginal Ring (IVR) Technology Highlights ➤Vaginal drug delivery offers many potential advantages due to large surface area, dense network of blood vessels and high elasticity due to presence of smooth muscle fibers. ➤Recognized advantages include comparable ease of administration and ability
Slide 37: DARE-HRT1
37 DARE-HRT1* Combination bio-identical estradiol + bio-identical progesterone 28- day IVR for hormone therapy following menopause. There are no FDA approved options with both hormones in one monthly IVR. Over 45M women in U.S. approaching or in menopause1 Hormone Therapy (HT) HT remains the most ef
Slide 38: DARE-FRT1 and DARE-PTB1
38 DARE-FRT1 and DARE-PTB1* Bio-identical progesterone 14-day IVR for prevention of preterm birth and luteal phase support as part of an IVF treatment plan. There are currently no FDA approved products marketed in the U.S. that do not require daily dosing of progesterone. Prevention of Preterm Birth
Slide 39: DARE-VVA1
39 DARE-VVA1* Proprietary tamoxifen formulation for vaginal administration for vulvar and vaginal atrophy (VVA), a chronic condition characterized by pain during intercourse, vaginal dryness and irritation. There are currently no FDA approved products labeled for VVA treatment in HR+ breast cancer.
Slide 40: DARE-VVA1 - Proof of Concept
40 Vaginal Tamoxifen Enrollment (Baseline) On Treatment (Month 3) Paired Difference (Baseline vs. Month 3) Median Vaginal pH Normal vaginal pH is usually less than 4.5. 2 7.1 range 6.5 to 7.5 5.0 range 5.0 to 5.2 - 2.0 median range - 2.5 to - 1.5 Lower pH value is a measure of symptom relief Vaginal
Slide 41: DARE-VVA1 – Phase 1/2 Study
41 DARE-VVA1 – Phase 1/2 Study Phase 1/2 study1 is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA and is being conducted by the Company’s wholly owned subsidiary in Australia. • The Phase 1/2 study will e
Slide 42: ADARE 204/214
42 ADARE 204/214* Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility. There are currently no FDA approved injectable contraceptives available indicated for 6-12 months protectio
Slide 43: DARE-LARC1
43 DARE-LARC1* Through June 2021 June 2021 – Nov. 2026 Long-Acting, Reversible Personal Contraceptive System – levonorgestrel-releasing implant drug delivery system designed to store and precisely deliver hundreds of therapeutic doses over years that a woman can turn on and off herself, according to
Slide 44: DARE-GML
Women often experience multiple episodes of vaginal infection in a year, and treatments for one condition may increase the likelihood of developing another condition.3 GML has multiple properties that make it an attractive active pharmaceutical ingredient (API) to potentially treat and/or prevent va
Slide 45: Daré Financial Highlights Snapshot
45 Funding sources: •Since inception, we have raised cash through sale of equity securities, M&A transactions, warrant and option exercises, non- dilutive grants, and license fees •We endeavor to be creative and opportunistic in seeking capital required to advance our candidates, and to be efficient
Slide 46: Daré – Working to Accelerate Innovation in Women's Health
46 Daré – Working to Accelerate Innovation in Women’s Health 2019 and 2020 Positive findings of Sildenafil Cream, 3.6% thermography clinical study Positive topline data for Ovaprene® postcoital test clinical study Exclusive licensing agreement with Bayer for Ovaprene Strategic partnerships w
Slide 47: Daring to Be Different and Advancing Products Women Want
47 DARING TO BE DIFFERENT® AND ADVANCING PRODUCTS WOMEN WANT NASDAQ: DARE www.darebioscience.com DARE TO BE BOLD